Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

This Cannabis Co. Earned a 100% Revenue Increase Over 3 Consecutive Quarters

Featured Submission, Featured Submission
0 Comments| April 21, 2021

{{labelSign}}  Favorites
{{errorMessage}}


(Click image to play video)

Avicanna Inc. (TSX: AVCN, OTCQX: AVCNF, Forum) is a diversified and vertically integrated Canadian biopharmaceutical Company that is focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

AVCN’s research is mainly conducted at its R&D headquarters in Toronto’s Johnson & Johnson Innovation Centre in collaboration with leading Canadian academic and medical institutions.

Its product lines include: the derma cosmetic Pura H&W offering, as well as its RHO Phyto medical cannabis line, which is available across Canada in partnership with Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart.

The company manages its own supply chain from cultivation and extraction through its two majority-owned subsidiaries - Sativa Nativa SAS and Santa Marta Golden Hemp SAS in Santa Marta, Colombia. Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients.

In this video, Avicanna’s Chief Executive Officer Aras Azadian offers a corporate update for shareholders, dicing into his company’s recent efforts to develop, manufacture, and commercialize plant-derived cannabinoid-based products for its pharmaceutical pipeline.

For more information, please visit www.avicanna.com.


FULL DISCLOSURE: Avicanna Inc. is a client of Stockhouse Publishing.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company